Implementation and Evaluation of a Screening Tool for Sexual Dysfunction for Pediatric Cancer Survivors
- Institution
- UNIVERSITY OF COLORADO DENVER, CO
- Principal investigator
- Jenna Demedis
- Funding
- $216K
- Duration
- 2022–2027
Moonbase score
Still being scored
Abstract
PROJECT SUMMARY/ABSTRACT Background: Sexual dysfunction (SD) is estimated to occur in up to 50% of childhood cancer survivors (CCS) and has important implications for quality of life and mental health. Effective management of SD in AYA-CCS is substantially limited due to lack of screening and detection of SD in cancer survivorship settings. Adolescent and young adult-aged CCS (AYA-CCS) may be particularly vulnerable to SD and its under-recognition due to developmental challenges. This study addresses this critical barrier and serves as the first step in progressing toward the long-term goal of improving health-related quality of life in AYA CCS through improved screening, recognition and treatment of SD among CCS. Candidate: The proposed award will enable the candidate, Dr. Sopfe, to develop the skills necessary to progress toward her career as an independent researcher leading high quality pragmatic trials. Training: Specifically, Dr. Sopfe will gain experience in Dissemination & Implementation (D&I) science, pragmatic clinical trials, and mixed methods, which will propel her toward a research career aimed at developing and disseminating interventions to improve quality of life for CCS. In addition to experiential training through the research plan, Dr. Sopfe will benefit from a multidisciplinary mentorship team: Primary Mentor, Dr. Peterson (hybrid trials, qualitative research, patient-reported outcomes); Co-Mentor, Dr. Chow (pediatric cancer survivorship, clinical trials); and Methods Mentor, Dr. Studts (D&I, mixed methods). Dr. Sopfe’s training plan includes formal didactic coursework, workshops, and career development programs. Research Plan: This proposal’s overall objective is to use patient and provider stakeholder input to refine and test an approach to SD screening for AYA CCS in a clinic setting. Informed by D&I frameworks, this research proposal will used mixed methods and iterative testing and modification to refine an SD screening approach (Aim 1). This approach will be then tested in a pilot type 1 hybrid effectiveness-implementation study (Aims 2 and 3), employing mixed methods to assess patient and provider outcomes. Environment: The environment for this project is exceptional with a strong academic Section of Pediatric Hematology/Oncology/BMT at the University of Colorado, the resources of the University of Colorado Adult and Child Consortium for Health Outcomes Research and Delivery Science (ACCORDS) (D&I Science Program, Qualitative & Mixed Methods Research Core). The clinical trial will occur through the 1) Children’s Hospital Colorado (CHCO) HOPE Survivorship Program; CHCO Neuro-Oncology group; and 3) Seattle Children’s Hospital Cancer Survivorship Program. This multiclinic design will ensure successful recruitment as well as increase generalizability of findings. Impact: The proposed study will serve as a necessary first step in improving screening, detection, and treatment of SD in AYA-CCS; future work will include establishing broader effectiveness our screening approach through a multicenter randomized trial, as well as development, testing, and dissemination of multidisciplinary interventions for SD in this population.
LOADING MOONBASE SCORE
Questions for UNIVERSITY OF COLORADO DENVER
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NIH · University of Colorado Denver70
Impact of Aiolos on intestinal intraepithelial lymphocytes
Kentaro Yomogida · $162K · 2022–2027
- NIH · University of Colorado Denver65
Administrative supplement to Exosome Biomarkers in concussion and Alzheimer's.
Ann-Charlotte Esther Granholm-Bentley · $107K · 2021–2026
- NIH · University of Colorado Denver62
How do astrocytes remodel the nervous system?
Yunsik Kang · $224K · 2022–2027